- Part 2: For the preceding part double click ID:nRSM0646Ua
13,470 8,912 738 908 10,558
Revenues from external customers in the Group's domicile - "United Kingdom",
as well as its other major markets, "Rest of the World" - have been identified
on the basis of internal management reporting systems, which are also used for
VAT purposes.
Human healthcare revenues were derived from a large number of customers,
including £3,499m from a single customer which makes up 30% of this segment's
revenue (2013: £2.050m being 23%). Animal healthcare revenues were derived
from a number of customers, with the largest customer accountable for £0.209m,
which represents 27% of revenue (2013: 6.6% from a single customer).
During the year 26% of the Group's revenues were earned from a single customer
(2013: 19.4%).
The Group's non-current assets are divided into the following geographical
areas:-
2014 2013
£'000 £'000
United Kingdom 7,455 7,567
Rest of the World 126 132
Non-current assets 7,581 7,699
4. TAXATION
The taxation charge represents:
2014 2013
£'000 £'000
Current taxation:-
Corporation tax 248 79
Adjustment in respect of earlier years (125) 7
Total current tax 123 86
Deferred tax:-
Origination and reversal of temporary differences 428 (524)
Total deferred tax 428 (524)
Total tax charge/(credit) in Income Statement 551 (438)
Factors affecting the tax charge/(credit):
The tax assessed for the year differs from the standard rate of corporation
tax in the UK. The difference is explained below:
2014 2013
£'000 £'000
Profit/(loss) on ordinary activities before tax 1,823 (1,750)
Profit/(loss) on ordinary activities
multiplied by the standard rate of corporation tax
in the UK of 22.50% (2013: 23.75%) 410 (416)
Effects of:
Expenses not deductible for tax purposes 139 116
Different rate tax bands and change in tax rates 1 18
Enhanced relief on qualifying scientific research expenditure (93) (135)
Adjustment in respect of prior years (125) 7
Income not taxable (11) -
Tax losses not utilised and other timing differences 230 (28)
Total tax charge/(credit) for year 551 (438)
5. DIVIDENDS
2014 2013
Amounts recognised as distributions to equity holders in the year: £'000 £'000
Ordinary shares of 1p each
Final dividend for the year ended 30 June 2013 of 0.32p
(2012: 0.35p) per share 128 140
Interim dividend for the year ended 30 June 2014 of 0.36p
(2013: 0.08p) per share 144 32
272 172
Proposed final dividend for the year ended 30 June 2014of 1.26p (2013: 0.32p) per share 507 128
The proposed final dividend is subject to approval by shareholders at the
forthcoming Annual General Meeting and has not been included as a liability in
the financial statements.
6. EARNINGS PER SHARE
The calculations of earnings per share are based on the following profits and
numbers of shares:
2014 2013
£'000 £'000
Retained profit/(loss) for the financial year attributable to equity holders of the parent 1,298 (1,264)
Shares '000Number Shares '000Number
Weighted average number of ordinary shares for the purpose of basic earnings per share 39,989 39,985
Effect of dilutive potential ordinary shares
Share options -
39,989 39,985
Earnings/(loss) per ordinary share
Basic 3.25p (3.16p)
Diluted 3.25p (3.16p)
7. NON RECURRING ITEMS
There were no non-recurring items in the year. In the prior year a review and
restructure of the business took place and as a result headcount fell by 15%;
the operation in China was restructured to cease the drain on cash; and the IP
portfolio in the Balance Sheet was reviewed with the result that certain
assets relating to legacy products were impaired. These 'root and branch
review' activities culminated in a non-cash exceptional charge of £2.2 million
for the year ended 30 June 2013.
8. CALLED UP SHARE CAPITAL
Allotted, issued and fully paid Number: £
30 June 2013 39,984,701 400,000
Issued during the year 250,000 2,000
30 June 2014 40,234,701 402,000
250,000 ordinary shares of 1 pence each, related to the exercise of 250,000
share options were issued during the year (2013:nil), for a total
consideration of £135,000, being £2,000 equity and £133,000 share premium. The
weighted average exercise price was 53.86 pence.
9. ANNUAL REPORT
The annual report and financial statements will be available on the company's
website www.tristel.com from 13 October 2014. Printed copies will be posted
to shareholders prior to the Company's Annual General Meeting taking place on
16 December 2014 in Snailwell, Newmarket.
This information is provided by RNS
The company news service from the London Stock Exchange